Diabetes
More Controversy Surrounding The Diabetes Drug Avandia
The mainstream has finally caught up with HSI again.
In 2003 we first told you about a link between the diabetes drug Avandia and an increased risk of congestive heart failure. Now, three and a half years later, the New England Journal of Medicine (NEJM) has made headlines with a study that illustrates just how expansive this danger really is.
But here's what the recent headlines haven't mentioned: Increased risk of heart attack is just part of Avandia's risk profile.
Slow going
You might wonder how the US Food and Drug Administration (FDA) responded to the NEJM study. On the very day the study was published online, FDA officials issued a safety alert. That's an impressive lightning-fast response to controversy. Meanwhile, response to safety is not quite as swift: According to an agency spokesman, the FDA has been evaluating Avandia heart risks for nearly 10 months.
And here's the frosting on the cake. Dr. Robert J. Meyer of the FDA's Center for Drug Evaluation and Research offered this explanation to the Associated Press: 'We've tried to weigh the risks of going forward with an uncertain message...with the level of uncertainty about the safety signal before us.'
To read the rest of the article click here
Click here to send to a friendShare thisPrinter friendly version
